scholarly journals Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients

2019 ◽  
Vol 25 (4) ◽  
pp. 743-748 ◽  
Author(s):  
Maura Faraci ◽  
Maria Grazia Calevo ◽  
Stefano Giardino ◽  
Massimiliano Leoni ◽  
Erica Ricci ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Pediatric Patients ◽  
Host Disease ◽  
Graft Versus Host ◽  
Steroid Refractory ◽  
Acute Graft

scholarly journals The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients

2013 ◽  
Vol 18 (1) ◽  
pp. 94-102 ◽  
Author(s):  
Pooja Khandelwal ◽  
Julia Lawrence ◽  
Alexandra H. Filipovich ◽  
Stella M. Davies ◽  
Jacob J. Bleesing ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Pediatric Patients ◽  
Host Disease ◽  
Graft Versus Host ◽  
Steroid Refractory ◽  
Acute Graft

scholarly journals Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Comparisons

2021 ◽  
Vol 8 (1) ◽  
pp. 10-17
Author(s):  
Gabriel Tremblay ◽  
Dimitrios Tomaras ◽  
Eric Strati ◽  
Anna Forsythe
Keyword(s):  
Adverse Events ◽  
Graft Versus Host Disease ◽  
Pediatric Patients ◽  
Inadequate Response ◽  
Host Disease ◽  
Graft Versus Host ◽  
Treatment Comparison ◽  
Grade Iii ◽  
Steroid Refractory ◽  
Acute Graft

Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be a lifesaving treatment for hematologic malignancies, but acute graft-versus-host-disease (aGVHD) is a potentially deadly adverse effect experienced by up to half of allo-HSCT recipients. Inadequate response to steroid therapy for aGVHD is associated with poor prognosis and high mortality, including among pediatric patients, who are the focus of this study. Ruxolitinib and remestemcel-L-rknd were evaluated for the treatment of steroid-refractory (SR) aGVHD in two separate single-arm trials. To effectively compare the safety and efficacy of these treatments without a head-to-head trial, a simulated treatment comparison (STC) was conducted. Methods: Regression techniques were used to adjust individual patient-level data from the remestemcel-L-rknd trial to mutually reported baseline characteristics from the ruxolitinib trial. Outcomes of interest included a 28-day overall response rate (ORR), a 28-day ORR in the grade III-IV aGVHD population, and adverse events (AEs). Results: In the full populations, the STC of risk ratios (RRs) found treatment with remestemcel-L-rknd to be associated with a numerical but not statistically significant improvement in the 28-day ORR versus ruxolitinib. In the grade III-IV aGVHD sub-group, the STC showed significantly improved 28-day ORR for remestemcel-L-rknd versus ruxolitinib (P=0.04). Remestemcel-L-rknd was also associated with improved safety outcomes (P<0.05) in 17 out of 30 AEs, including hematologic events, peripheral edema, muscular weakness, nausea, back pain, and fatigue. Conclusion: Remestemcel-L-rknd was associated with significant improvements in day 28 ORR compared with ruxolitinib in patients with severe (grade III-IV) SR aGVHD. Across all grades of SR aGVHD, remestemcel-L-rknd was associated with fewer all-grade treatment-emergent adverse events (TEAEs) (27/30) available for comparison, including the majority reaching statistical significance.

Sign in / Sign up

Export Citation Format

Share Document